Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 April 2024 | Story André Damons | Photo Supplied
Dr Milton Mogotsi
Dr Milton Mogotsi graduated on Thursday with the degree Doctor of Philosophy with specialisation in Virology during the Faculty of Health Sciences at the University of the Free State (UFS) autumn graduation ceremonies.

A pilot study for his master’s degree not only ignited Dr Milton Mogotsi’s passion but he was also inspired by the fact that this was a newly emerging field of research in the discipline of virology at the time. This eventually led to him pursuing a PhD and ing on his research.

Dr Mogotsi graduated on Thursday (18 April) with the degree Doctor of Philosophy with specialisation in Virology during the Faculty of Health Sciences at the University of the Free State (UFS) autumn graduation ceremonies. Prof Martin Nyaga, Head of the Next Generation Sequencing Unit (UFS-NGS) and an associate professor in the Division of Virology, was his promotor and Prof Trudi O’Neill from the Department of Microbiology and Biochemistry his co-promotor.

“It feels great! It was exhausting and overwhelming at times, but that light at the end of the tunnel will start to be brighter. I feel so proud of myself and very free. Nothing beats that liberating feeling that I have successfully completed a doctoral degree and now a new chapter of my life begins. I believe this post-PhD period is an excellent time for reflecting on my attributes and revising my CV, and with a PhD degree under my belt, I look forward to an abundance of opportunities that will soon open up,” says Dr Mogotsi after graduating.

Research

According to him, he was first introduced into this research concept when he was doing his master’s degree in microbiology. “Although it was more of a pilot study aiming to assess the feasibility of conducting this type of research on a larger scale, we made some interesting findings which we published in an international journal.

“I obtained my degree with distinction, receiving an award for Best Master’s Dissertation in Microbiology. The findings of this research really ignited my passion, and I was also inspired by the fact that this was a newly emerging field of research in the discipline of virology at the time, and of course in my master’s research there were some gaps and limitations which needed to be addressed. I then took a decision to pursue a PhD and expand on that research, and working with new-born babies is always enjoyable,” says Dr Mogotsi. 

With his thesis titled “Longitudinal characterisation of the enteric virome of infants from the Free State, South Africa, using viral metagenomics”, Dr Mogotsi’s research aimed to characterise the total assemblage of all viruses that colonise the gastrointestinal tract of newborns, often referred to as the gut virome, using metagenomics.

“We know that the human gut undergoes some changes as the new-born baby becomes exposed to the numerous microorganisms, such as viruses, from the immediate environment. This once-in-a-lifetime occurrence can have life-long effects on the health and disease state of humans. Viral intestinal infections are among the leading causes of childhood hospitalisations and deaths, especially in Africa, and infants are at a greater risk of suffering severe illnesses due to their immature immune system,” he explains.

According to him, previous research had focused more on the investigating the population of bacteria present in the gut of new-borns, therefore, there’s a huge knowledge gap about viruses colonising this part of the human body. In South Africa, more attention has been on assessing the effectiveness of currently available vaccines and surveillance of specific disease-causing viruses such as rotavirus.

The research he was conducting, he continues, therefore, sought to characterise all intestinal viruses in healthy new-borns individuals, their source of origin, the changes in diversity and composition occurring over time, as well as their potential implications on the health of infants. “The findings of my study have provided more insights into what is known or new viruses are colonising the infants’ gut, as well as their evolution over time”, he adds.

PhD journey

Even though he had to put his PhD on hold for a year due to COVID-19, but with the resilience, persistence, and his ability to clear the roadblocks that were in his way, he managed to complete it. He also credits his supportive mentors and a community of colleagues and friends for their unwavering support throughout his academic journey.

“After a year-long delay, I was able to go ahead with the project and everything went well from sample collection and sample processing in the lab. The challenging part was analysing and interpreting the data as this involved advanced bioinformatics, but in the end, I was able to find solutions and make sense out of the results I got. The study was a great success with two publications in peer-reviewed international journals emanating from this study.

“Furthermore, I had an opportunity to present my research in local and international conferences. I have been to Ghana, Nigeria and Indonesia. Locally, I presented in a conference in Johannesburg and in Cape Town. More exciting was participating in the Three Minute Thesis (3MT) competition in which I emerged victorious, winning the National 3MT competition. The other award I received was from the Faculty of Health Sciences Research Forum, winning the Dr Lehlohonolo Mathengtheng Trophy for best PhD presentation”, says Dr Mogotsi.

Motivation

Dr Mogotsi says the fact that he comes from the township and received his secondary education from a township school always kept him motivated. He is well aware that there are many who look up to him, who are also inspired by what he has achieved.

“More importantly, my supervisor, Prof Nyaga, was very supportive and he is very active in his research field with genuine interest in student projects, while making time to provide adequate supervision and mentorship. His high standards of ensuring that students graduate with a strong publication record is commendable.”

As a coordinator of wet lab activities at the UFS-NGS Unit, Dr Mogotsi is currently involved in several projects as the unit is a World Health Organisation Collaborating Center for Vaccine Preventable Diseases and Pathogen Genomics. They are doing collaborative projects with several partners across the continent on the genomic surveillance of enteric viruses such as rotavirus, norovirus, sapovirus, astrovirus and adenoviruses. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept